IMVT
Price
$16.39
Change
+$0.64 (+4.06%)
Updated
Jun 26 closing price
Capitalization
2.8B
40 days until earnings call
XENE
Price
$32.16
Change
-$0.03 (-0.09%)
Updated
Jun 27, 11:26 AM (EDT)
Capitalization
2.47B
41 days until earnings call
Interact to see
Advertisement

IMVT vs XENE

Header iconIMVT vs XENE Comparison
Open Charts IMVT vs XENEBanner chart's image
Immunovant
Price$16.39
Change+$0.64 (+4.06%)
Volume$957.7K
Capitalization2.8B
Xenon Pharmaceuticals
Price$32.16
Change-$0.03 (-0.09%)
Volume$937
Capitalization2.47B
IMVT vs XENE Comparison Chart in %
Loading...
IMVT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XENE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
IMVT vs. XENE commentary
Jun 27, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IMVT is a Buy and XENE is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 27, 2025
Stock price -- (IMVT: $16.39 vs. XENE: $32.20)
Brand notoriety: IMVT and XENE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: IMVT: 79% vs. XENE: 89%
Market capitalization -- IMVT: $2.8B vs. XENE: $2.47B
IMVT [@Biotechnology] is valued at $2.8B. XENE’s [@Biotechnology] market capitalization is $2.47B. The market cap for tickers in the [@Biotechnology] industry ranges from $301.01B to $0. The average market capitalization across the [@Biotechnology] industry is $2.32B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

IMVT’s FA Score shows that 0 FA rating(s) are green whileXENE’s FA Score has 1 green FA rating(s).

  • IMVT’s FA Score: 0 green, 5 red.
  • XENE’s FA Score: 1 green, 4 red.
According to our system of comparison, XENE is a better buy in the long-term than IMVT.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

IMVT’s TA Score shows that 7 TA indicator(s) are bullish while XENE’s TA Score has 3 bullish TA indicator(s).

  • IMVT’s TA Score: 7 bullish, 3 bearish.
  • XENE’s TA Score: 3 bullish, 4 bearish.
According to our system of comparison, IMVT is a better buy in the short-term than XENE.

Price Growth

IMVT (@Biotechnology) experienced а +3.34% price change this week, while XENE (@Biotechnology) price change was +0.94% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +3.59%. For the same industry, the average monthly price growth was +34.25%, and the average quarterly price growth was +14.95%.

Reported Earning Dates

IMVT is expected to report earnings on Aug 06, 2025.

XENE is expected to report earnings on Aug 07, 2025.

Industries' Descriptions

@Biotechnology (+3.59% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
IMVT($2.8B) has a higher market cap than XENE($2.47B). XENE YTD gains are higher at: -17.857 vs. IMVT (-33.831). XENE has higher annual earnings (EBITDA): -290.36M vs. IMVT (-437.78M). IMVT has more cash in the bank: 714M vs. XENE (550M). IMVT has less debt than XENE: IMVT (98K) vs XENE (8.68M). XENE has higher revenues than IMVT: XENE (7.5M) vs IMVT (0).
IMVTXENEIMVT / XENE
Capitalization2.8B2.47B113%
EBITDA-437.78M-290.36M151%
Gain YTD-33.831-17.857189%
P/E RatioN/AN/A-
Revenue07.5M-
Total Cash714M550M130%
Total Debt98K8.68M1%
FUNDAMENTALS RATINGS
IMVT vs XENE: Fundamental Ratings
IMVT
XENE
OUTLOOK RATING
1..100
599
VALUATION
overvalued / fair valued / undervalued
1..100
44
Fair valued
76
Overvalued
PROFIT vs RISK RATING
1..100
10046
SMR RATING
1..100
9795
PRICE GROWTH RATING
1..100
6460
P/E GROWTH RATING
1..100
1004
SEASONALITY SCORE
1..100
2750

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

IMVT's Valuation (44) in the null industry is in the same range as XENE (76) in the Biotechnology industry. This means that IMVT’s stock grew similarly to XENE’s over the last 12 months.

XENE's Profit vs Risk Rating (46) in the Biotechnology industry is somewhat better than the same rating for IMVT (100) in the null industry. This means that XENE’s stock grew somewhat faster than IMVT’s over the last 12 months.

XENE's SMR Rating (95) in the Biotechnology industry is in the same range as IMVT (97) in the null industry. This means that XENE’s stock grew similarly to IMVT’s over the last 12 months.

XENE's Price Growth Rating (60) in the Biotechnology industry is in the same range as IMVT (64) in the null industry. This means that XENE’s stock grew similarly to IMVT’s over the last 12 months.

XENE's P/E Growth Rating (4) in the Biotechnology industry is significantly better than the same rating for IMVT (100) in the null industry. This means that XENE’s stock grew significantly faster than IMVT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
IMVTXENE
RSI
ODDS (%)
Bearish Trend 1 day ago
81%
Bullish Trend 1 day ago
82%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
77%
Bearish Trend 1 day ago
79%
Momentum
ODDS (%)
Bullish Trend 1 day ago
77%
Bearish Trend 1 day ago
77%
MACD
ODDS (%)
Bullish Trend 1 day ago
80%
Bullish Trend 1 day ago
79%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
78%
Bullish Trend 1 day ago
74%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
81%
Bullish Trend 1 day ago
74%
Advances
ODDS (%)
Bullish Trend 22 days ago
77%
Bullish Trend 8 days ago
72%
Declines
ODDS (%)
Bearish Trend 5 days ago
84%
Bearish Trend 11 days ago
75%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
84%
N/A
Aroon
ODDS (%)
Bullish Trend 1 day ago
88%
Bearish Trend 1 day ago
84%
View a ticker or compare two or three
Interact to see
Advertisement
IMVT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XENE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
AEPGX60.090.67
+1.13%
American Funds EUPAC A
IGIUX101.550.55
+0.54%
Integrity Growth & Income Fund C
CVFYX15.57N/A
N/A
Victory Pioneer Disciplined Value Y
AVEGX50.23N/A
N/A
Ave Maria Growth
FLKSX15.35N/A
N/A
Fidelity Low-Priced Stock K6